vs

Side-by-side financial comparison of ALBANY INTERNATIONAL CORP (AIN) and CLOVER HEALTH INVESTMENTS, CORP. (CLOV). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $321.2M, roughly 1.5× ALBANY INTERNATIONAL CORP). ALBANY INTERNATIONAL CORP runs the higher net margin — 4.3% vs -10.1%, a 14.4% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 12.0%). ALBANY INTERNATIONAL CORP produced more free cash flow last quarter ($51.4M vs $-69.0M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs 1.2%).

Albany International Corp is a global advanced materials and industrial technology company. It operates two core segments: Machine Clothing producing custom engineered fabrics for paper and other industrial manufacturing processes, and Engineered Composites developing high-performance composite components primarily for the aerospace and defense sectors, serving customers across North America, Europe, Asia and other global regions.

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

AIN vs CLOV — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.5× larger
CLOV
$487.7M
$321.2M
AIN
Growing faster (revenue YoY)
CLOV
CLOV
+32.8% gap
CLOV
44.7%
12.0%
AIN
Higher net margin
AIN
AIN
14.4% more per $
AIN
4.3%
-10.1%
CLOV
More free cash flow
AIN
AIN
$120.4M more FCF
AIN
$51.4M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
1.2%
AIN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AIN
AIN
CLOV
CLOV
Revenue
$321.2M
$487.7M
Net Profit
$13.9M
$-49.3M
Gross Margin
31.1%
Operating Margin
9.3%
-10.1%
Net Margin
4.3%
-10.1%
Revenue YoY
12.0%
44.7%
Net Profit YoY
-21.5%
-123.2%
EPS (diluted)
$0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AIN
AIN
CLOV
CLOV
Q4 25
$321.2M
$487.7M
Q3 25
$261.4M
$496.6M
Q2 25
$311.4M
$477.6M
Q1 25
$288.8M
$462.3M
Q4 24
$286.9M
$337.0M
Q3 24
$298.4M
$331.0M
Q2 24
$332.0M
$356.3M
Q1 24
$313.3M
$346.9M
Net Profit
AIN
AIN
CLOV
CLOV
Q4 25
$13.9M
$-49.3M
Q3 25
$-97.8M
$-24.4M
Q2 25
$9.2M
$-10.6M
Q1 25
$17.4M
$-1.3M
Q4 24
$17.7M
$-22.1M
Q3 24
$18.0M
$-9.2M
Q2 24
$24.6M
$7.4M
Q1 24
$27.3M
$-19.2M
Gross Margin
AIN
AIN
CLOV
CLOV
Q4 25
31.1%
Q3 25
-19.1%
Q2 25
31.3%
Q1 25
33.4%
Q4 24
31.5%
Q3 24
30.3%
24.5%
Q2 24
33.9%
30.3%
Q1 24
34.7%
23.6%
Operating Margin
AIN
AIN
CLOV
CLOV
Q4 25
9.3%
-10.1%
Q3 25
-44.6%
-4.9%
Q2 25
7.2%
-2.2%
Q1 25
9.8%
-0.3%
Q4 24
8.5%
-6.4%
Q3 24
8.4%
-2.7%
Q2 24
12.9%
2.0%
Q1 24
12.4%
-6.5%
Net Margin
AIN
AIN
CLOV
CLOV
Q4 25
4.3%
-10.1%
Q3 25
-37.4%
-4.9%
Q2 25
2.9%
-2.2%
Q1 25
6.0%
-0.3%
Q4 24
6.2%
-6.6%
Q3 24
6.0%
-2.8%
Q2 24
7.4%
2.1%
Q1 24
8.7%
-5.5%
EPS (diluted)
AIN
AIN
CLOV
CLOV
Q4 25
$0.56
Q3 25
$-3.37
Q2 25
$0.31
Q1 25
$0.56
Q4 24
$0.57
Q3 24
$0.57
Q2 24
$0.79
Q1 24
$0.87

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AIN
AIN
CLOV
CLOV
Cash + ST InvestmentsLiquidity on hand
$112.3M
$78.3M
Total DebtLower is stronger
$455.7M
Stockholders' EquityBook value
$726.2M
$308.7M
Total Assets
$1.7B
$541.0M
Debt / EquityLower = less leverage
0.63×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AIN
AIN
CLOV
CLOV
Q4 25
$112.3M
$78.3M
Q3 25
$108.3M
Q2 25
$106.7M
Q1 25
$119.4M
Q4 24
$115.3M
$194.5M
Q3 24
$127.2M
$288.0M
Q2 24
$116.4M
$254.8M
Q1 24
$125.4M
$208.3M
Total Debt
AIN
AIN
CLOV
CLOV
Q4 25
$455.7M
Q3 25
$480.6M
Q2 25
$444.7M
Q1 25
$416.4M
Q4 24
$318.5M
Q3 24
$362.2M
Q2 24
$377.1M
Q1 24
$439.1M
Stockholders' Equity
AIN
AIN
CLOV
CLOV
Q4 25
$726.2M
$308.7M
Q3 25
$739.3M
$340.9M
Q2 25
$888.6M
$344.2M
Q1 25
$900.0M
$336.1M
Q4 24
$943.5M
$341.1M
Q3 24
$991.0M
$342.2M
Q2 24
$967.5M
$324.9M
Q1 24
$967.5M
$292.5M
Total Assets
AIN
AIN
CLOV
CLOV
Q4 25
$1.7B
$541.0M
Q3 25
$1.7B
$559.7M
Q2 25
$1.7B
$575.0M
Q1 25
$1.7B
$583.7M
Q4 24
$1.6B
$580.7M
Q3 24
$1.8B
$653.0M
Q2 24
$1.8B
$674.2M
Q1 24
$1.8B
$671.8M
Debt / Equity
AIN
AIN
CLOV
CLOV
Q4 25
0.63×
Q3 25
0.65×
Q2 25
0.50×
Q1 25
0.46×
Q4 24
0.34×
Q3 24
0.37×
Q2 24
0.39×
Q1 24
0.45×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AIN
AIN
CLOV
CLOV
Operating Cash FlowLast quarter
$73.7M
$-66.9M
Free Cash FlowOCF − Capex
$51.4M
$-69.0M
FCF MarginFCF / Revenue
16.0%
-14.1%
Capex IntensityCapex / Revenue
6.9%
0.4%
Cash ConversionOCF / Net Profit
5.31×
TTM Free Cash FlowTrailing 4 quarters
$82.6M
$-69.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AIN
AIN
CLOV
CLOV
Q4 25
$73.7M
$-66.9M
Q3 25
$43.9M
$12.1M
Q2 25
$32.7M
$5.4M
Q1 25
$2.1M
$-16.3M
Q4 24
$78.5M
$34.8M
Q3 24
$47.0M
$50.0M
Q2 24
$83.4M
$44.8M
Q1 24
$9.6M
$25.9M
Free Cash Flow
AIN
AIN
CLOV
CLOV
Q4 25
$51.4M
$-69.0M
Q3 25
$25.9M
$11.4M
Q2 25
$18.8M
$4.8M
Q1 25
$-13.5M
$-16.5M
Q4 24
$60.2M
$33.3M
Q3 24
$31.6M
$49.6M
Q2 24
$63.6M
$44.4M
Q1 24
$-17.3M
$25.5M
FCF Margin
AIN
AIN
CLOV
CLOV
Q4 25
16.0%
-14.1%
Q3 25
9.9%
2.3%
Q2 25
6.0%
1.0%
Q1 25
-4.7%
-3.6%
Q4 24
21.0%
9.9%
Q3 24
10.6%
15.0%
Q2 24
19.2%
12.5%
Q1 24
-5.5%
7.3%
Capex Intensity
AIN
AIN
CLOV
CLOV
Q4 25
6.9%
0.4%
Q3 25
6.9%
0.1%
Q2 25
4.5%
0.1%
Q1 25
5.4%
0.0%
Q4 24
6.4%
0.5%
Q3 24
5.2%
0.1%
Q2 24
6.0%
0.1%
Q1 24
8.6%
0.1%
Cash Conversion
AIN
AIN
CLOV
CLOV
Q4 25
5.31×
Q3 25
Q2 25
3.56×
Q1 25
0.12×
Q4 24
4.44×
Q3 24
2.61×
Q2 24
3.39×
6.04×
Q1 24
0.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AIN
AIN

Transferred At Point In Time$176.5M55%
Engineered Composites Other$99.3M31%
Engineered Composites ASC$44.5M14%
Transferred Over Time$1.0M0%

CLOV
CLOV

Segment breakdown not available.

Related Comparisons